Gain Therapeutics, Inc. (GANX) Research

Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.

Market snapshot

Symbol
GANX
Price
$1.88
Day change
+5.62%
Market cap
$80.2M
P/E ratio
-3.74x
52-week range
1.41-4.34
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$10.00

Peer companies

  • Adicet Bio, Inc. (ACET)
  • Adagene Inc. (ADAG)
  • CervoMed Inc. (CRVO)
  • Fortress Biotech, Inc. (FBIO)
  • Lite Strategy, Inc. (LITS)
  • NRx Pharmaceuticals, Inc. (NRXP)
  • Nutriband Inc. (NTRB)
  • OS Therapies Incorporated (OSTX)

Recent insider activity

  • Mack Gene — A-Award (200000 shares) on 2026-03-24
  • Fuggetta Gianluca — A-Award (50000 shares) on 2026-03-24
  • Islam Khalid — A-Award (15000 shares) on 2025-06-24
  • Nicaise Claude — A-Award (15000 shares) on 2025-06-24
  • Riley Jeffrey Scott — A-Award (15000 shares) on 2025-06-24

Open Gain Therapeutics, Inc. (GANX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.